$6.68
2.27%
Nasdaq, Apr 21, 08:46 pm CET
ISIN
US03152W1099
Symbol
FOLD
Sector
Industry

Amicus Therapeutics, Inc. Stock price

$6.83
-2.29 25.11% 1M
-5.14 42.94% 6M
-2.59 27.49% YTD
-3.72 35.26% 1Y
-1.10 13.87% 3Y
-4.67 40.61% 5Y
-5.17 43.08% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.13 1.94%
ISIN
US03152W1099
Symbol
FOLD
Sector
Industry

Key metrics

Market capitalization $2.10b
Enterprise Value $2.29b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.34
P/S ratio (TTM) P/S ratio 3.97
P/B ratio (TTM) P/B ratio 10.53
Revenue growth (TTM) Revenue growth 32.29%
Revenue (TTM) Revenue $528.30m
EBIT (operating result TTM) EBIT $34.06m
Free Cash Flow (TTM) Free Cash Flow $-37.44m
Cash position $249.95m
EPS (TTM) EPS $-0.18
P/E forward 282.25
P/S forward 3.33
EV/Sales forward 3.63
Short interest 6.06%
Show more

Is Amicus Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Amicus Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Amicus Therapeutics, Inc. forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Amicus Therapeutics, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Amicus Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
528 528
32% 32%
100%
- Direct Costs 61 61
36% 36%
12%
467 467
32% 32%
88%
- Selling and Administrative Expenses 315 315
18% 18%
60%
- Research and Development Expense 109 109
28% 28%
21%
43 43
165% 165%
8%
- Depreciation and Amortization 8.55 8.55
9% 9%
2%
EBIT (Operating Income) EBIT 34 34
146% 146%
6%
Net Profit -56 -56
63% 63%
-11%

In millions USD.

Don't miss a Thing! We will send you all news about Amicus Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amicus Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about 8 hours ago
PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025.
Neutral
GlobeNewsWire
14 days ago
PHILADELPHIA, April 07, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company's long-term investors.
Neutral
Seeking Alpha
about one month ago
Amicus Therapeutics, Inc., with two approved rare disease therapies, shows strong revenue growth and market potential despite a 30% stock decline since 2021. Galafold and Pombiliti+Opfolda are driving revenue, with significant market share and potential label expansions, targeting $1bn revenue by 2028. The company has a solid financial position, minimal near-term competition, and a favorable pa...
More Amicus Therapeutics, Inc. News

Company Profile

Amicus Therapeutics, Inc. is a biotechnology company. It engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product includes migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Head office United States
CEO Bradley Campbell
Employees 499
Founded 2002
Website www.amicusrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today